JP2008050375A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008050375A5 JP2008050375A5 JP2007294088A JP2007294088A JP2008050375A5 JP 2008050375 A5 JP2008050375 A5 JP 2008050375A5 JP 2007294088 A JP2007294088 A JP 2007294088A JP 2007294088 A JP2007294088 A JP 2007294088A JP 2008050375 A5 JP2008050375 A5 JP 2008050375A5
- Authority
- JP
- Japan
- Prior art keywords
- drug carrier
- vitamin
- activity
- analog
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003937 drug carrier Substances 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 9
- 210000004500 stellate cell Anatomy 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 7
- 150000004492 retinoid derivatives Chemical class 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 5
- 150000002266 vitamin A derivatives Chemical class 0.000 claims 5
- 206010016654 Fibrosis Diseases 0.000 claims 4
- 239000000470 constituent Substances 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 230000004761 fibrosis Effects 0.000 claims 3
- 230000035755 proliferation Effects 0.000 claims 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 210000002744 extracellular matrix Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 210000001260 vocal cord Anatomy 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 1
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 claims 1
- 102000015427 Angiotensins Human genes 0.000 claims 1
- 108010064733 Angiotensins Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 claims 1
- 101000836383 Homo sapiens Serpin H1 Proteins 0.000 claims 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 claims 1
- 102000000536 PPAR gamma Human genes 0.000 claims 1
- 108010016731 PPAR gamma Proteins 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 102100027287 Serpin H1 Human genes 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 108010052164 Sodium Channels Proteins 0.000 claims 1
- 102000018674 Sodium Channels Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 claims 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000000693 micelle Substances 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 230000036573 scar formation Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 235000019155 vitamin A Nutrition 0.000 claims 1
- 239000011719 vitamin A Substances 0.000 claims 1
- 229940045997 vitamin a Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007294088A JP4533420B2 (ja) | 2004-12-22 | 2007-11-13 | 線維化抑制のための薬物担体および薬物担体キット |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004382791 | 2004-12-22 | ||
| JP2007294088A JP4533420B2 (ja) | 2004-12-22 | 2007-11-13 | 線維化抑制のための薬物担体および薬物担体キット |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006549061A Division JP4121537B2 (ja) | 2004-12-22 | 2005-12-22 | 線維化抑制のための薬物担体および薬物担体キット |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010049297A Division JP5172880B2 (ja) | 2004-12-22 | 2010-03-05 | 線維化抑制のための薬物担体および薬物担体キット |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008050375A JP2008050375A (ja) | 2008-03-06 |
| JP2008050375A5 true JP2008050375A5 (enrdf_load_stackoverflow) | 2009-12-17 |
| JP4533420B2 JP4533420B2 (ja) | 2010-09-01 |
Family
ID=39234728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007294088A Active JP4533420B2 (ja) | 2004-12-22 | 2007-11-13 | 線維化抑制のための薬物担体および薬物担体キット |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4533420B2 (enrdf_load_stackoverflow) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120269886A1 (en) | 2004-12-22 | 2012-10-25 | Nitto Denko Corporation | Therapeutic agent for pulmonary fibrosis |
| CA2595517C (en) | 2004-12-22 | 2013-09-24 | Sapporo Medical University | Drug carrier and drug carrier kit for inhibiting fibrosis |
| US9572886B2 (en) | 2005-12-22 | 2017-02-21 | Nitto Denko Corporation | Agent for treating myelofibrosis |
| TWI407971B (zh) | 2007-03-30 | 2013-09-11 | Nitto Denko Corp | Cancer cells and tumor-related fibroblasts |
| EP2610343A3 (en) | 2008-11-26 | 2013-09-25 | Chugai Seiyaku Kabushiki Kaisha | Method for designing siRNA and oligoribonucleotides inhibiting HCV |
| JP5600299B2 (ja) | 2008-11-26 | 2014-10-01 | 中外製薬株式会社 | ベシクル製剤 |
| CN105473147A (zh) * | 2013-04-24 | 2016-04-06 | 萨克生物研究学院 | 维生素d受体/smad基因组回路门纤维化反应 |
| WO2019023149A1 (en) | 2017-07-24 | 2019-01-31 | Salk Institute For Biological Studies | USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911928A (en) * | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
| AU2001247924A1 (en) * | 2000-03-29 | 2001-10-08 | Aradigm Corporation | Cationic liposomes |
| JP2002047211A (ja) * | 2000-08-04 | 2002-02-12 | Japan Science & Technology Corp | 脂溶性物質と生理活性高分子物質結合体および細胞核内への導入方法 |
| CA2595517C (en) * | 2004-12-22 | 2013-09-24 | Sapporo Medical University | Drug carrier and drug carrier kit for inhibiting fibrosis |
-
2007
- 2007-11-13 JP JP2007294088A patent/JP4533420B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011201890A5 (enrdf_load_stackoverflow) | ||
| JP2008050375A5 (enrdf_load_stackoverflow) | ||
| Olejarz et al. | Exosomes in angiogenesis and anti-angiogenic therapy in cancers | |
| JP2010138188A5 (enrdf_load_stackoverflow) | ||
| Gao et al. | Injectable immunotherapeutic hydrogel containing RNA-loaded lipid nanoparticles reshapes tumor microenvironment for pancreatic cancer therapy | |
| Sadakierska-Chudy | MicroRNAs: diverse mechanisms of action and their potential applications as cancer epi-therapeutics | |
| Rosińska et al. | Tumor vessels fuel the fire in glioblastoma | |
| Born et al. | Therapeutic potential of extracellular vesicle‐associated long noncoding RNA | |
| Liu et al. | Targeted delivery of antisense inhibitor of miRNA for antiangiogenesis therapy using cRGD-functionalized nanoparticles | |
| Kinoh et al. | Nanomedicines eradicating cancer stem-like cells in vivo by pH-triggered intracellular cooperative action of loaded drugs | |
| Kouri et al. | miRNA-182 and the regulation of the glioblastoma phenotype-toward miRNA-based precision therapeutics | |
| Hamada et al. | Novel therapeutic strategies targeting tumor-stromal interactions in pancreatic cancer | |
| Kheshtchin et al. | Targeting hypoxia and hypoxia‐inducible factor‐1 in the tumor microenvironment for optimal cancer immunotherapy | |
| Kaur et al. | Modified mRNA as a therapeutic tool for the heart | |
| Wu et al. | Improving the intracellular drug concentration in lung cancer treatment through the codelivery of doxorubicin and miR-519c mediated by porous PLGA microparticle | |
| Pathak et al. | Role of angiogenesis and its biomarkers in development of targeted tumor therapies | |
| Spugnini et al. | Preclinical models in electrochemotherapy: the role of veterinary patients | |
| RU2017136720A (ru) | Средство для лечения фиброза почек | |
| Syed et al. | Exosomal and non-exosomal microRNAs: new kids on the block for cancer therapy | |
| Sun et al. | RNA binding proteins in extracellular vesicles and their potential value for cancer diagnosis and treatment | |
| Gulati et al. | Exosomes as theranostic targets: implications for the clinical prognosis of aggressive cancers | |
| Hanieh et al. | Aryl hydrocarbon receptor as an anticancer target: an overview of ten years odyssey | |
| Obisi et al. | Unveiling the future of cancer stem cell therapy: a narrative exploration of emerging innovations | |
| Beigi et al. | Lipid-based nanocarriers for targeted gene delivery in Lung Cancer Therapy: exploring a Novel Therapeutic paradigm | |
| Maphutha et al. | The role of the PTEN tumor suppressor gene and its Anti-Angiogenic activity in melanoma and other cancers |